Support price reduction jokes

Because the state has organized centralized procurement of coronary stents to alleviate the problem of expensive medical treatment for the masses.

There are many patients with cardiovascular diseases in China, and cardiac stent is one of the commonly used consumables for treating cardiovascular diseases. The urgent needs of patients and the huge market have caused the high price of heart stents, but patients and their families have to accept this reality.

The average price of heart stents will be from 1.3 million to 700, which is shocking. According to relevant data, before this centralized procurement, the average price of heart stents in China was around 1.3 million, but after this centralized procurement, the average price of heart stents plummeted to around 700 yuan. Compared with last year, the average price of similar products of the same enterprise is 93%, the average price of domestic products is 92%, and the average price of imported products is 95%.

This price reduction is unbelievable. Tens of thousands of heart stents suddenly become hundreds of dollars, which makes many patients happy, but also has doubts, and some even question their quality.

The conditions for competitive bidding for cardiac stents are mature, and the state organizes centralized procurement with quantity, reducing intermediate circulation links. Heart stents belong to high-value medical consumables, which are underwritten by agents after leaving the factory. After layers of agency, there is a big gap between ex-factory price and human price. Due to the large clinical dosage, manufacturers are fully competitive. Full bid? Conditions are ripe, and cardiac stents have become the first batch of high-value medical consumables purchased by the state.

According to the introduction of relevant departments, the essence of quantity procurement is to compress the circulation link, basically taking goods from manufacturers and sending them directly to patients, which not only reduces the economic burden of patients, but also saves the marketing cost of manufacturers, thus further reducing costs.

The sharp price reduction of heart stents is good news for patients; National centralized procurement, manufacturers more worry-free. National centralized procurement with quantity has built a bridge between manufacturers and patients, which is a profound stroke of medical reform.

It is believed that with the deepening of medical reform, more high-value medical products will be reduced in price, which can greatly alleviate the problem of expensive medical treatment for the masses.